Mountain Valley MD

We are here to change the world by delivering unprecedented technologies for the nutraceutical, vaccine and pharmaceutical markets, making the seemingly impossible, a reality.

MOUNTAIN VALLEY MD AWARDED CANADIAN PATENT FOR ITS QUICKSOME™ TECHNOLOGY

January 14, 2021

“The mission we are on to eradicate the world from Polio is not a coincidence. Nothing we are doing is unintentional. We celebrate the change makers before us and among us.”

-  Dennis Hancock, President & CEO, Mountain Valley MD

"We now have the best pharmacokinetic data for Ivermectin in the world and the implications for both human and animal health are tremendous,”

-  Mike Farber, Chief Science Officer at Mountain Valley MD

“The Ivermectin drug is being shown to be indispensable in treating endo and ectoparasites but also emerging as a leading therapeutic for COVID-19 treatments, The unprecedented Ivermectin intramuscular injection uptake of 15 minutes is the key to shutting down viral spreads quickly, directly contributing to the elimination of morbidity and mortality, and MVMD has created a 20-year patent around this breakthrough Ivermectin application.”

-  Dennis Hancock, President & CEO of Mountain Valley MD

“MVMD has succeeded in making a Nobel prize winning wonder drug even better based on overcoming its number one limitation of solubility.”

-  Mike Farber, Chief Science Officer at Mountain Valley MD

A testimony of Dr. Pierre Kory to the US Homeland Security Committee on the mountain of evidence indicating that Ivermectin can immediately prevent COVID-19 deaths.

"MVMD notes the testimony of Dr. Pierre Kory, a member of the Front-Line COVID-19 Critical Care Alliance, to the US Homeland Security Committee this week, during which he referenced mounting evidence of the effectiveness of Ivermectin as a therapeutic for COVID-19. The data Dr. Kory referenced touts the ability of the drug Ivermectin to prevent COVID-19, to keep those with early symptoms from progressing to the hyper- inflammatory phase of the disease, and even to help critically ill patients recover."

“Dr. Kory’s testimony outlining evidence that Ivermectin can immediately prevent COVID19 deaths may be a watershed moment not just for Mountain Valley MD, but for the entire world, Watching that commentary was such a validation of the important work our team is doing and the immediate impact our technology can have on global human and animal health.”

-  Dennis Hancock, President & CEO of Mountain Valley MD

INfinite Possibility.

Company Mission.

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective oral dissolving product formats.

Patented Quicksol™ technology for macrocyclic lactones, including Ivermectin and Selamectin, to enable injection or liquid application of poorly soluble drugs to enhance bioavailability orally and transdermally.

Our Value Proposition

We provide our partners with unprecedented market advantages while dealing with some of the most significant challenges facing their companies.

Loss of Patent Exclusivity

Extending Profitability Against Generic Drug Competitors

Driving Down Drug and Vaccine Costs While Increasing Profitability

Enabling Broader Distribution of Drugs and Vaccines

Expanding Production Capacity for Global Blockbuster Drugs

Eliminating Significant Costs and Wastage Associated with Cold Chain Storage Requirements

Our Value.

Our Progress

December 10, 2020

MOUNTAIN VALLEY MD CONFIRMS 800% INCREASE IN IVERMECTIN ABSORPTION WITH SOLUBILIZATION TECHNOLOGY IN PRE-CLINICAL TRIAL

Read Press Release
December 14, 2020

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES STRATEGIC PRIVATE PLACEMENT OFFERING OF UNITS, APPOINTMENT OF ADVISOR BOARD MEMBERS, AND PROPOSED DEBT SETTLEMENT

Read Press Release
December 22, 2020

MOUNTAIN VALLEY MD HOLDINGS OVERSUBSCRIBES STRATEGIC PRIVATE PLACEMENT OFFERING OF UNITS

Read Press Release
December 24, 2020

MOUNTAIN VALLEY MD FILES FOR ACCELERATION OF PATENT EXAMINATION FOR SOLUBILIZED IVERMECTIN

Read Press Release
December 29, 2020

MOUNTAIN VALLEY MD COMPLETES STRATEGIC SALE OF SUBSIDIARY, FINALIZING QUICKSOME™ LICENSE AGREEMENT

Read Press Release
January 11, 2021

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES APPLICATION FOR OTCQB LISTING IN U.S., PROVIDES UPDATE ON WARRANT EXERCISES

Read Press Release
January 14, 2021

MOUNTAIN VALLEY MD AWARDED CANADIAN PATENT FOR ITS QUICKSOME™ TECHNOLOGY

Read Press Release
Read All News

Current News

“We believe this discovery to be a breakthrough that will enable the efficacy needed to treat respiratory infections such as COVID-19, influenza and tuberculosis by enabling the drug deposition into the airways and lungs through aerosol formulations and pulmonary delivery.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“The extrapolation of this technology achievement across multiple viral applications could be very significant and has the potential to positively impact human and animal health globally.”

- Dennis Hancock,
  President & CEO of Mountain Valley MD
  

“A needle-free, cost-effective, polio vaccine could be a major step towards global polio eradication. Mountain Valley MD’s Quicksome™ technology has already proven its ability to stabilize and preserve the Inactivated Poliovirus Vaccine (IPV) and I believe that this technology holds great promise in finally delivering a needle-free effective sublingual polio vaccine and probably many other globally needed vaccines as well.”

- Dr. John Clements,
  Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“The FDA’s Polio D Antigen preservation results demonstrate that Mountain Valley MD’s proprietary and patented Quicksome™ low temperature strip manufacturing technology can be successfully applied to heat labile vaccines, complex proteins such as insulin or glucagon, peptides and other molecules and constructs that are sensitive to heat and oxidation.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“With encouraging FDA Polio Lab validation, Mountain Valley MD is continuing work on development of our proprietary vaccine adjuvants for Polio and the necessary pre-clinical trials to demonstrate the unprecedented impact of our Quicksome™ technology.”

- Dennis Hancock, President and CEO of Mountain Valley MD

“For decades scientists have been working to solve the problem of vaccine instability and cold chain distribution with little progress. Approaches such as micro-needle applications, lyophilization, spray drying, and others have not reached commercialization due to problems of complexity, cost, and long-term stability challenges.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“We believe Mountain Valley MD’s patented Quicksome™ technology revolutionizes drug and nutraceutical ingredient delivery for superior health outcomes by simultaneously addressing a multitude of key drug and nutraceutical product efficacy challenges, such as low bioavailability, high absorption variability and poor dosage control.”

- Dennis Hancock, President and CEO of Mountain Valley MD

“Many of the active ingredients contained in traditional pharmaceutical drugs and nutraceutical supplements are not well absorbed and suffer extensive degradation during first pass metabolism.  We feel this is exactly the problem that Mountain Valley MD’s direct-to-mouth Quicksome™ technology solves, dramatically improving bioavailability of compounds that are traditionally heavily metabolized by MAO enzymes, glucuronidation and other conjugation processes”.

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“We have an amazingly talented team that is working on solving some very advanced challenges in the health and wellness space.  To date we have done research and development work with more than 60 molecules for a variety of nutraceutical and pharmaceutical applications, including drugs, vaccines, the emerging mushroom space and cannabinoids.”

- Dennis Hancock, President and CEO of Mountain Valley MD

“For me personally, the idea that our delivery technology could help dispense drugs such as insulin or deliver vaccines into the body through a rapid dissolve sublingual strip and eliminate the need for painful needle injections is truly game changing.”

- Dennis Hancock, President and CEO of Mountain Valley MD
Our Progress.
Our Progress.

Subscribe for Updates

Stay plugged in on everything Mountain Valley MD.

THANK YOU FOR YOUR INTEREST IN OUR STORY.
Please check your inbox to confirm your subscription.
Oops! Something went wrong while submitting the form.
*By Clicking "Sign Up" You agree to Mountain Valley MD's Privacy Policy
Subscribe